

CRITICAL THERAPEUTICS INC

Form SC 13D/A

February 21, 2007

OMB APPROVAL
OMB Number: 3235-0145
Expires: February 28, 2009
Estimated average burden
hours per response...14.5

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 13D

**Under the Securities Exchange Act of 1934
(Amendment No. 1)***

CRITICAL THERAPEUTICS, INC.
(Name of Issuer)

COMMON STOCK, PAR VALUE \$0.001 PER SHARE
(Title of Class of Securities)

22674T 10 5

(CUSIP Number)

LUKE EVNIN

MPM ASSET MANAGEMENT
THE JOHN HANCOCK TOWER
200 CLARENDON STREET, 54TH FLOOR
BOSTON, MASSACHUSETTS 02116
TELEPHONE: (617) 425-9200

(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)

FEBRUARY 13, 2007

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 22674T 10 5

NAMES OF REPORTING PERSONS:

MPM BioVentures II-QP, L.P

1

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

2

(a)

(b) (1)

SEC USE ONLY:

3

SOURCE OF FUNDS (SEE INSTRUCTIONS):

4

WC

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

5

CITIZENSHIP OR PLACE OF ORGANIZATION:

6

Delaware

SOLE VOTING POWER:

7

NUMBER OF 2,722,072 (2)

SHARED VOTING POWER:

SHARES BENEFICIALLY OWNED BY 8

0

EACH
REPORTING PERSON **9** SOLE DISPOSITIVE POWER:
2,722,072 (2)

WITH
10 SHARED DISPOSITIVE POWER:
0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
2,722,072 (2)

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
o

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):
6.46%(3)

14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
PN

(1) This Schedule is filed by MPM BioVentures II-QP, L.P. (BVQP), MPM BioVentures II, L.P. (BV), MPM Asset Management Investors 2001 LLC (AM), MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG (KG), MPM Asset Management II, L.P. (AM II), MPM Asset Management II LLC (AM LLC), Luke Evnin, Ansbert Gadicke, Kurt Wheeler, Michael Steinmetz and Nicholas Galakatos (collectively, the MPM Entities). The MPM Entities expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes warrants to purchase 129,181 shares of common stock exercisable within 60 days of February 13, 2007.

(3) This percentage is calculated based upon 42,005,535 shares of the Issuer s common stock outstanding (as of November 7, 2006), as set forth in the Issuer s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2006.

CUSIP No. 22674T 10 5

NAMES OF REPORTING PERSONS:

MPM BioVentures II, L.P

1

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

2

(a)

(b) (1)

SEC USE ONLY:

3

SOURCE OF FUNDS (SEE INSTRUCTIONS):

4

WC

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

5

CITIZENSHIP OR PLACE OF ORGANIZATION:

6

Delaware

SOLE VOTING POWER:

7

NUMBER OF 300,389 (2)

SHARED VOTING POWER:

SHARES BENEFICIALLY OWNED BY 8

0

EACH
REPORTING PERSON **9** SOLE DISPOSITIVE POWER:
300,389 (2)

WITH
10 SHARED DISPOSITIVE POWER:
0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
300,389 (2)

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
o

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):
0.71%(3)

14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
PN

(1) This Schedule is filed by MPM BioVentures II-QP, L.P. (BVQP), MPM BioVentures II, L.P. (BV), MPM Asset Management Investors 2001 LLC (AM), MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG (KG), MPM Asset Management II, L.P. (AM II), MPM Asset Management II LLC (AM LLC), Luke Evnin, Ansbert Gadicke, Kurt Wheeler, Michael Steinmetz and Nicholas Galakatos (collectively, the MPM Entities). The MPM Entities expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes warrants to purchase 14,256 shares of common stock exercisable within 60 days of February 13, 2007.

(3) This percentage is calculated based upon 42,005,535 shares of the Issuer s common stock outstanding (as of November 7, 2006), as set forth in the Issuer s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2006.

CUSIP No. 22674T 10 5

NAMES OF REPORTING PERSONS:

MPM Asset Management Investors 2001 LLC

1

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

2

(a)

(b) (1)

SEC USE ONLY:

3

SOURCE OF FUNDS (SEE INSTRUCTIONS):

4

WC

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

5

CITIZENSHIP OR PLACE OF ORGANIZATION:

6

Delaware

SOLE VOTING POWER:

7

NUMBER OF 56,523 (2)

SHARED VOTING POWER:

SHARES BENEFICIALLY OWNED BY 8

0

EACH
REPORTING PERSON **9** SOLE DISPOSITIVE POWER:
56,523 (2)

WITH
10 SHARED DISPOSITIVE POWER:
0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
56,523 (2)

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
o

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):
0.13%(3)

14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
OO

(1) This Schedule is filed by MPM BioVentures II-QP, L.P. (BVQP), MPM BioVentures II, L.P. (BV), MPM Asset Management Investors 2001 LLC (AM), MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG (KG), MPM Asset Management II, L.P. (AM II), MPM Asset Management II LLC (AM LLC), Luke Evnin, Ansbert Gadicke, Kurt Wheeler, Michael Steinmetz and Nicholas Galakatos (collectively, the MPM Entities). The MPM Entities expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes warrants to purchase 2,682 shares of common stock exercisable within 60 days of February 13, 2007.

(3) This percentage is calculated based upon 42,005,535 shares of the Issuer s common stock outstanding (as of November 7, 2006), as set forth in the Issuer s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2006.

CUSIP No. 22674T 10 5

NAMES OF REPORTING PERSONS:

1

MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

2

- (a)
- (b) (1)

SEC USE ONLY:

3

SOURCE OF FUNDS (SEE INSTRUCTIONS):

4

WC

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

5

CITIZENSHIP OR PLACE OF ORGANIZATION:

6

Germany

SOLE VOTING POWER:

7

NUMBER OF 958,498 (2)

SHARED VOTING POWER:

SHARES
BENEFICIALLY OWNED BY 8

0

CUSIP No. 22674T 10 5

NAMES OF REPORTING PERSONS:

MPM Asset Management II, L.P.

1

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

2

(a)

(b) (1)

SEC USE ONLY:

3

SOURCE OF FUNDS (SEE INSTRUCTIONS):

4

WC

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

5

CITIZENSHIP OR PLACE OF ORGANIZATION:

6

Delaware

SOLE VOTING POWER:

7

NUMBER OF 0

SHARED VOTING POWER:

SHARES BENEFICIALLY OWNED BY 8

4,037,482 (2)

EACH REPORTING PERSON	9	SOLE DISPOSITIVE POWER: 0
WITH	10	SHARED DISPOSITIVE POWER: 4,037,482 (2)

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

4,037,482 (2)

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

o

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

9.57%(3)

14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

PN

(1) This Schedule is filed by MPM BioVentures II-QP, L.P. (BVQP), MPM BioVentures II, L.P. (BV), MPM Asset Management Investors 2001 LLC (AM), MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG (KG), MPM Asset Management II, L.P. (AM II), MPM Asset Management II LLC (AM LLC), Luke Evnin, Ansbert Gadicke, Kurt Wheeler, Michael Steinmetz and Nicholas Galakatos (collectively, the MPM Entities). The MPM Entities expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes warrants to purchase 129,181 shares of common stock held by BVQP, warrants to purchase 14,256 shares of common stock held by BV., warrants to purchase 2,682 shares of common stock held by AM and warrants to purchase 45,487 shares of common stock held by KG. Such warrants are exercisable within 60 days of February 13, 2007.

(3) This percentage is calculated based upon 42,005,535 shares of the Issuer s common stock outstanding (as of November 7, 2006), as set forth in the Issuer s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2006.

CUSIP No. 22674T 10 5

NAMES OF REPORTING PERSONS:

MPM Asset Management II LLC

1

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

2

(a)

(b) (1)

SEC USE ONLY:

3

SOURCE OF FUNDS (SEE INSTRUCTIONS):

4

WC

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

5

CITIZENSHIP OR PLACE OF ORGANIZATION:

6

Delaware

SOLE VOTING POWER:

7

NUMBER OF 0

SHARED VOTING POWER:

SHARES BENEFICIALLY OWNED BY 8

4,037,482 (2)

EACH		SOLE DISPOSITIVE POWER:
REPORTING	9	
PERSON		0
WITH		SHARED DISPOSITIVE POWER:
	10	
		4,037,482 (2)

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
4,037,482 (2)

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
o

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):
9.57%(3)

14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
OO

(1) This Schedule is filed by MPM BioVentures II-QP, L.P. (BVQP), MPM BioVentures II, L.P. (BV), MPM Asset Management Investors 2001 LLC (AM), MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG (KG), MPM Asset Management II, L.P. (AM II), MPM Asset Management II LLC (AM LLC), Luke Evnin, Ansbert Gadicke, Kurt Wheeler, Michael Steinmetz and Nicholas Galakatos (collectively, the MPM Entities). The MPM Entities expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes warrants to purchase 129,181 shares of common stock held by BVQP, warrants to purchase 14,256 shares of common stock held by BV., warrants to purchase 2,682 shares of common stock held by AM and warrants to purchase 45,487 shares of common stock held by KG. Such warrants are exercisable within 60 days of February 13, 2007.

(3) This percentage is calculated based upon 42,005,535 shares of the Issuer s common stock outstanding (as of November 7, 2006), as set forth in the Issuer s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2006.

CUSIP No. 22674T 10 5

NAMES OF REPORTING PERSONS:

Luke Evinin

1

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

2

(a)

(b) (1)

SEC USE ONLY:

3

SOURCE OF FUNDS (SEE INSTRUCTIONS):

4

WC

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

5

CITIZENSHIP OR PLACE OF ORGANIZATION:

6

United States

SOLE VOTING POWER:

7

NUMBER OF 7,226

SHARED VOTING POWER:

SHARES BENEFICIALLY OWNED BY 8

4,037,482 (2)

EACH
REPORTING PERSON **9** SOLE DISPOSITIVE POWER:
7,226

WITH
10 SHARED DISPOSITIVE POWER:
4,037,482 (2)

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
4,044,708 (2)

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
o

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):
9.57%(3)

14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
IN

(1) This Schedule is filed by MPM BioVentures II-QP, L.P. (BVQP), MPM BioVentures II, L.P. (BV), MPM Asset Management Investors 2001 LLC (AM), MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG (KG), MPM Asset Management II, L.P. (AM II), MPM Asset Management II LLC (AM LLC), Luke Evnin, Ansbert Gadicke, Kurt Wheeler, Michael Steinmetz and Nicholas Galakatos (collectively, the MPM Entities). The MPM Entities expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes warrants to purchase 129,181 shares of common stock held by BVQP, warrants to purchase 14,256 shares of common stock held by BV, warrants to purchase 2,682 shares of common stock held by AM and warrants to purchase 45,487 shares of common stock held by KG. Such warrants are exercisable within 60 days of February 13, 2007. AM II and AM LLC are the direct and indirect general partners of BVQP, BV and KG. The reporting person is a member of AM II and AM.

(3) This percentage is calculated based upon 42,005,535 shares of the Issuer s common stock outstanding (as of November 7, 2006), as set forth in the Issuer s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2006.

CUSIP No. 22674T 10 5

NAMES OF REPORTING PERSONS:

1 Ansbert Gadicke

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

- (a)
- (b) (1)

3 SEC USE ONLY:

4 SOURCE OF FUNDS (SEE INSTRUCTIONS):

WC

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

6 CITIZENSHIP OR PLACE OF ORGANIZATION:

United States

7 SOLE VOTING POWER:

NUMBER OF 0

8 SHARED VOTING POWER:

SHARES BENEFICIALLY OWNED BY 4,037,482 (2)

EACH
REPORTING PERSON **9** SOLE DISPOSITIVE POWER:
0

WITH **10** SHARED DISPOSITIVE POWER:
4,037,482 (2)

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
4,037,482 (2)

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
o

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):
9.57%(3)

14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
IN

(1) This Schedule is filed by MPM BioVentures II-QP, L.P. (BVQP), MPM BioVentures II, L.P. (BV), MPM Asset Management Investors 2001 LLC (AM), MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG (KG), MPM Asset Management II, L.P. (AM II), MPM Asset Management II LLC (AM LLC), Luke Evnin, Ansbert Gadicke, Kurt Wheeler, Michael Steinmetz and Nicholas Galakatos (collectively, the MPM Entities). The MPM Entities expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes warrants to purchase 129,181 shares of common stock held by BVQP, warrants to purchase 14,256 shares of common stock held by BV, warrants to purchase 2,682 shares of common stock held by AM and warrants to purchase 45,487 shares of common stock held by KG. Such warrants are exercisable within 60 days of February 13, 2007. AM II and AM LLC are the direct and indirect general partners of BVQP, BV and KG. The reporting person is a member of AM II and AM.

(3) This percentage is calculated based upon 42,005,535 shares of the Issuer s common stock outstanding (as of November 7, 2006), as set forth in the Issuer s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2006.

CUSIP No. 22674T 10 5

NAMES OF REPORTING PERSONS:

1 Kurt Wheeler

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

2 (a)
(b) (1)

3 SEC USE ONLY:

4 SOURCE OF FUNDS (SEE INSTRUCTIONS):
WC

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

6 CITIZENSHIP OR PLACE OF ORGANIZATION:
United States

7 SOLE VOTING POWER:

NUMBER OF 452

SHARES SHARED VOTING POWER:
BENEFICIALLY **8**
OWNED BY 4,037,482 (2)

EACH
REPORTING PERSON **9** SOLE DISPOSITIVE POWER:
452

WITH **10** SHARED DISPOSITIVE POWER:
4,037,482 (2)

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
4,037,934 (2)

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
o

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):
9.57%(3)

14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
IN

(1) This Schedule is filed by MPM BioVentures II-QP, L.P. (BVQP), MPM BioVentures II, L.P. (BV), MPM Asset Management Investors 2001 LLC (AM), MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG (KG), MPM Asset Management II, L.P. (AM II), MPM Asset Management II LLC (AM LLC), Luke Evnin, Ansbert Gadicke, Kurt Wheeler, Michael Steinmetz and Nicholas Galakatos (collectively, the MPM Entities). The MPM Entities expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes warrants to purchase 129,181 shares of common stock held by BVQP, warrants to purchase 14,256 shares of common stock held by BV, warrants to purchase 2,682 shares of common stock held by AM and warrants to purchase 45,487 shares of common stock held by KG. Such warrants are exercisable within 60 days of February 13, 2007. AM II and AM LLC are the direct and indirect general partners of BVQP, BV and KG. The reporting person is a member of AM II and AM.

(3) This percentage is calculated based upon 42,005,535 shares of the Issuer s common stock outstanding (as of November 7, 2006), as set forth in the Issuer s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2006.

CUSIP No. 22674T 10 5

NAMES OF REPORTING PERSONS:

Michael Steinmetz

1

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

2

(a)

(b) (1)

SEC USE ONLY:

3

SOURCE OF FUNDS (SEE INSTRUCTIONS):

4

WC

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

5

CITIZENSHIP OR PLACE OF ORGANIZATION:

6

United States

SOLE VOTING POWER:

7

NUMBER OF 0

SHARED VOTING POWER:

SHARES BENEFICIALLY OWNED BY 8

4,037,482 (2)

EACH	SOLE DISPOSITIVE POWER:
REPORTING PERSON	9 0
WITH	SHARED DISPOSITIVE POWER:
	10 4,037,482 (2)

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
4,037,482 (2)

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
o

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):
9.57%(3)

14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
IN

(1) This Schedule is filed by MPM BioVentures II-QP, L.P. (BVQP), MPM BioVentures II, L.P. (BV), MPM Asset Management Investors 2001 LLC (AM), MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG (KG), MPM Asset Management II, L.P. (AM II), MPM Asset Management II LLC (AM LLC), Luke Evnin, Ansbert Gadicke, Kurt Wheeler, Michael Steinmetz and Nicholas Galakatos (collectively, the MPM Entities). The MPM Entities expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes warrants to purchase 129,181 shares of common stock held by BVQP, warrants to purchase 14,256 shares of common stock held by BV, warrants to purchase 2,682 shares of common stock held by AM and warrants to purchase 45,487 shares of common stock held by KG. Such warrants are exercisable within 60 days of February 13, 2007. AM II and AM LLC are the direct and indirect general partners of BVQP, BV and KG. The reporting person is a member of AM II and AM.

(3) This percentage is calculated based upon 42,005,535 shares of the Issuer s common stock outstanding (as of November 7, 2006), as set forth in the Issuer s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2006.

CUSIP No. 22674T 10 5

NAMES OF REPORTING PERSONS:

Nicholas Galakatos

1

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

2

(a)

(b) (1)

SEC USE ONLY:

3

SOURCE OF FUNDS (SEE INSTRUCTIONS):

4

WC

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

5

CITIZENSHIP OR PLACE OF ORGANIZATION:

6

United States

SOLE VOTING POWER:

7

NUMBER OF 674

SHARED VOTING POWER:

SHARES BENEFICIALLY OWNED BY 8

4,051,937 (2)

EACH
 REPORTING PERSON **9** SOLE DISPOSITIVE POWER:
 674

WITH **10** SHARED DISPOSITIVE POWER:
 4,051,937 (2)

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
 4,052,611 (2)

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
 o

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):
 9.60%(3)

14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
 IN

(1) This Schedule is filed by MPM BioVentures II-QP, L.P. (BVQP), MPM BioVentures II, L.P. (BV), MPM Asset Management Investors 2001 LLC (AM), MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG (KG), MPM Asset Management II, L.P. (AM II), MPM Asset Management II LLC (AM LLC), Luke Evnin, Ansbert Gadicke, Kurt Wheeler, Michael Steinmetz and Nicholas Galakatos (collectively, the MPM Entities). The MPM Entities expressly disclaim status as a group for purposes of this Schedule 13D.

(2) Includes warrants to purchase 129,181 shares of common stock held by BVQP, warrants to purchase 14,256 shares of common stock held by BV, warrants to purchase 2,682 shares of common stock held by AM and warrants to purchase 45,487 shares of common stock held by KG. Such warrants are exercisable within 60 days of February 13, 2007. AM II and AM LLC are the direct and indirect general partners of BVQP, BV and KG. The reporting person is a member of AM II and AM. Also includes 14,166 shares issuable upon exercise of options within 60 days of February 13, 2007 and 289 shares held by AAG Peakham, of which the reporting person is a member.

(3) This percentage is calculated based upon 42,005,535 shares of the Issuer s common stock outstanding (as of November 7, 2006), as set forth in the Issuer s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2006.

The following constitutes Amendment No. 1 to Schedule 13D filed by the undersigned (the Schedule 13D/A). This Schedule 13D/A is being filed by the MPM Entities to report the pro-rata distributions of securities beneficially owned by the MPM Entities to their respective limited and general partners, and in the case of certain of the MPM Entities, the receipt of shares via such distributions, as described in Item 5 below. Accordingly, the number of securities beneficially owned by the MPM Entities has decreased. The Schedule 13D/A is amended as follows and except as otherwise provided herein, all items of the Schedule 13D, as amended, remain unchanged.

Item 4. Purpose of Transaction

Item 4. Purpose of Transaction of the Schedule 13D is hereby amended by adding the following to the end thereof: On February 13, 2007, the MPM Entities distributed pro-rata to their respective limited and general partners an aggregate of 1,000,000 shares of the Issuer's Common Stock. MPM BioVentures II-QP, L.P., MPM BioVentures II, L.P., MPM Asset Management Investors 2001 LLC and MPM BioVentures, GmbH & Co. Parallel-Beteiligungs KG distributed 674,200, 74,400, 14,000 and 237,400 shares of the Issuer's Common Stock, respectively.

Item 5. Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer is hereby amended and restated in its entirety as follows: The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this Statement is provided as of February 16, 2007:

MPM Entity	Shares Held	Warrants Held Directly	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Beneficial Ownership	Percentage of Class (2)
MPM BioVentures II-QP, L.P.	2,592,891	129,181	2,722,072	0	2,722,072	0	2,722,072	6.46%
MPM BioVentures II, L.P.	286,133	14,256	300,389	0	300,389	0	300,389	0.71%
MPM Asset Management Investors 2001 LLC	53,841	2,682	56,523	0	56,523	0	56,523	0.13%
MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG	913,011	45,487	958,498	0	958,498	0	958,498	2.28%
MPM Asset Management II, L.P.(1)	0	0	0	4,037,482	0	4,037,482	4,037,482	9.57%
MPM Asset Management II LLC(1)	0	0	0	4,037,482	0	4,037,482	4,037,482	9.57%
Luke Evnin(1)	7,226	0	7,226	4,037,482	7,226	4,037,482	4,044,708	9.58%
Ansbert Gadicke(1)	0	0	0	4,037,482	0	4,037,482	4,037,482	9.57%
Kurt Wheeler(1)	452	0	452	4,037,482	452	4,037,482	4,037,934	9.57%
Michael Steinmetz(1)	0	0	0	4,037,482	0	4,037,482	4,037,482	9.57%
Nicholas Galakatos(1)(3)	674	0	674	4,051,937	674	4,051,937	4,052,611	9.60%

(1) MPM Asset Management II, L.P. and MPM Asset Management II LLC own no securities of the Issuer directly.

MPM Asset Management II, L.P. and MPM Asset Management II LLC are the direct and indirect general partners of MPM BioVentures II-QP, L.P., MPM BioVentures II, L.P. and MPM BioVentures GmbH & Co.

Parallel-Beteiligungs KG. Luke Evnin, Ansbert Gadicke, Kurt Wheeler, Michael Steinmetz and Nicholas

Galakatos are members of AM II and AM.

- (2) These percentages are calculated based upon 42,005,535 shares of the Issuer's common stock outstanding (as of November 7, 2006), as set forth in the Issuer's most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2006.
- (3) Includes 14,166 shares issuable upon exercise of options within 60 days of February 13, 2007 and 289 shares held by AAG Peakham, of which the reporting person is a member.

Item 7. Material to Be Filed as Exhibits

- A. Form of Securities Purchase Agreement between the Issuer and certain Purchasers, dated June 6, 2005 (Incorporated by reference to Exhibit 99.1 to the Issuer's Current Report on Form 8-K filed on June 7, 2005 (SEC File No. 000-50767)).
- B. Agreement regarding filing of joint Schedule 13D/A.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 20, 2007

MPM BioVentures II-QP, L.P.

By: MPM Asset Management II,
L.P.,
its General Partner

By: MPM Asset Management II
LLC,
its General Partner

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Investment Manager

MPM BioVentures II, L.P.

By: MPM Asset Management II,
L.P.,
its General Partner

By: MPM Asset Management II
LLC,
its General Partner

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Investment Manager

MPM Asset Management Investors 2001 LLC

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Investment Manager

MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG

By: MPM Asset Management II,
L.P.,
in its capacity as its Special
Limited Partner

By: MPM Asset Management II
LLC,
its General Partner

By: /s/ Luke Evin

Name: Luke Evin
Title: Investment Manager

MPM Asset Management II, L.P.

By: MPM Asset Management II
LLC,
its General Partner

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Investment Manager

MPM Asset Management II LLC

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Investment Manager

/s/ Luke Evnin

Luke Evnin

/s/ Ansbert Gadicke

Ansbert Gadicke

/s/ Kurt Wheeler

Kurt Wheeler

/s/ Michael Steinmetz

Michael Steinmetz

/s/ Nicholas Galakatos

Nicholas Galakatos

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

**Attention: Intentional misstatements or omissions of fact
constitute Federal criminal violations (See 18 U.S.C. 1001)**

SCHEDULE I

General Partners/Members:

Luke Evnin

c/o MPM Asset Management

The John Hancock Tower

200 Clarendon Street, 54th Floor

Boston, Massachusetts 02116

Principal Occupation: Member of the general partners of MPM BioVentures II-QP, L.P., MPM BioVentures II, L.P., MPM Asset Management Investors 2001 LLC, and MPM BioVentures GmbH & Co.

Parallel-Beteiligungs KG

Citizenship: USA

Ansbert Gadicke

c/o MPM Asset Management

The John Hancock Tower

200 Clarendon Street, 54th Floor

Boston, Massachusetts 02116

Principal Occupation: Member of the general partners of MPM BioVentures II-QP, L.P., MPM BioVentures II, L.P., MPM Asset Management Investors 2001 LLC, and MPM BioVentures GmbH & Co.

Parallel-Beteiligungs KG

Citizenship: USA

Nikolas Galakatos

c/o MPM Asset Management

The John Hancock Tower

200 Clarendon Street, 54th Floor

Boston, Massachusetts 02116

Principal Occupation: Member of the general partners of MPM BioVentures II-QP, L.P., MPM BioVentures II, L.P., MPM Asset Management Investors 2001 LLC, and MPM BioVentures GmbH & Co.

Parallel-Beteiligungs KG

Citizenship: USA

Michael Steinmetz

c/o MPM Asset Management

The John Hancock Tower

200 Clarendon Street, 54th Floor

Boston, Massachusetts 02116

Principal Occupation: Member of the general partners of MPM BioVentures II-QP, L.P., MPM BioVentures II, L.P., MPM Asset Management Investors 2001 LLC, and MPM BioVentures GmbH & Co.

Parallel-Beteiligungs KG

Citizenship: USA

Kurt Wheeler

c/o MPM Asset Management

The John Hancock Tower

200 Clarendon Street, 54th Floor

Boston, Massachusetts 02116

Principal Occupation: Member of the general partners of MPM BioVentures II-QP, L.P., MPM BioVentures II, L.P., MPM Asset Management Investors 2001 LLC, and MPM BioVentures GmbH & Co.

Parallel-Beteiligungs KG

Citizenship: USA

EXHIBIT INDEX

A. Form of Securities Purchase Agreement between the Issuer and certain Purchasers, dated June 6, 2005
(Incorporated by reference to Exhibit 99.1 to the Issuer's Current Report on Form 8-K filed on June 7, 2005 (SEC File No. 000-50767)).

B. Agreement regarding filing of joint Schedule 13D/A.

17

Exhibit B

JOINT FILING STATEMENT

I, the undersigned, hereby express my agreement that the attached amendment No. 1 to Schedule 13D (and any amendments thereto) relating to the common stock of Critical Therapeutics, Inc. is filed on behalf of each of the undersigned.

Date: February 20, 2007

MPM BioVentures II-QP, L.P.

By: MPM Asset Management II,
L.P.,
its General Partner

By: MPM Asset Management II
LLC,
its General Partner

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Investment Manager

MPM BioVentures II, L.P.

By: MPM Asset Management II,
L.P.,
its General Partner

By: MPM Asset Management II
LLC,
its General Partner

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Investment Manager

MPM Asset Management Investors 2001 LLC

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Investment Manager

MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG

By: MPM Asset Management II,
L.P.,
in its capacity as its Special

Limited Partner

By: MPM Asset Management II
LLC,
its General Partner

By: /s/ Luke Evin

Name: Luke Evin
Title: Investment Manager

MPM Asset Management II, L.P.

By: MPM Asset Management II
LLC,
its General Partner

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Investment Manager

MPM Asset Management II, LLC

By: /s/ Luke Evnin

Name: Luke Evnin
Title: Investment Manager

/s/ Luke Evnin

Luke Evnin

/s/ Ansbert Gadicke

Ansbert Gadicke

/s/ Kurt Wheeler

Kurt Wheeler

/s/ Michael Steinmetz

Michael Steinmetz

/s/ Nicholas Galakatos

Nicholas Galakatos